Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin™) by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells

International Journal of Oncology

Volumn 31, Issue 4, 2007, Pages 769-776

  Vazquez Martin, Alejandro ^a   Colomer, Ramon ^a   Brunet, Joan ^a   Menendez, Javier A ^a  

^a NONE

Author keywords

Breast cancer; Fatty acid synthase; HER2; Herceptin; Trastuzumab

Indexed keywords

4 METHYLENE 2 OCTYL 5 OXOFURAN 3 CARBOXYLIC ACID; 4-METHYLENE-2-OCTYL-5-OXOFURAN-3-CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FASN PROTEIN, HUMAN; FATTY ACID SYNTHASE; GAMMA BUTYROLACTONE; MESSENGER RNA; MONOCLONAL ANTIBODY; TRASTUZUMAB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST TUMOR; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; METABOLISM; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

4-BUTYROLACTONE; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FATTY ACID SYNTHETASE COMPLEX; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 35848962736     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.4.769     Document Type: Article

References (46)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A and McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182, 1987.
2. Hynes NE and Stern DF: The biology of erbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198: 165-184, 1994.
3. Neve RM, Lane HA and Hynes NE: The role of overexpressed HER2 in transformation. Ann Oncol 12 (suppl 1): S9-S13, 2001.
4. Yarden Y: Biology of HER2 and its importance in breast cancer. Oncology 61 (suppl 2): 1-13, 2001. (Pubitemid 33033419)
5. Rubin I and Yarden Y: The basic biology of HER2. Ann Oncol 12 (suppl 1): S3-S8, 2001.
6. Menard S, Pupa SM, Campiglio M and Tagliabue E: Biological and therapeutic role of HER2 in cancer. Oncogene 22: 6570-6578, 2003. (Pubitemid 37372337)
7. Pegram MD, Konecny G and Slamon DJ: The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of Herceptin (trastuzumab) therapy for breast cancer. Cancer Treat Res 103: 57-75, 2000.
8. Hayes DF and Thor AD: c-erbB-2 in breast cancer: development of a clinically useful marker. Semin Oncol 29: 231-245, 2002.
9. Choudhury A and Kiessling R: Her-2/neu as a paradigm of a tumor-specific target for therapy. Breast Dis 20: 25-31, 2004. (Pubitemid 39600443)
10. Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Targeted therapy in breast cancer: the HER-2/neu gene and protein. Mol Cell Proteomics 3: 379-398, 2004. (Pubitemid 38702091)
11. Arteaga CL: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122-130, 2003. (Pubitemid 36331971)
12. Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME and Shepard HM: Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285-4289, 1992.
13. Carter P, Fendly BM, Lewis GD and Sliwkowski MX: Development of Herceptin. Breast Dis 11: 103-111, 2000.
14. Harries M and Smith I: The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9: 75-85, 2002. (Pubitemid 34832161)
15. Nahta R and Esteva FJ: HER-2-targeted therapy: lessons learned and future directions. Clin Cancer Res 9: 5078-5084, 2003.
16. Lan KH, Lu CH and Yu D: Mechanisms of trastuzumab resistance and their clinical implications. Ann NY Acad Sci 1059: 70-75, 2005.
17. Nahta R, Yu D, Hung MC, Hortobagyi GN and Esteva FJ: Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280, 2006
18. Nahta R and Esteva FJ: Herceptin: mechanisms of actions and resistance. Cancer Lett 232: 123-138, 2006.
19. Gonzalez-Angulo AM, Hortobagyi GN and Esteva FJ: Adjuvant therapy with trastuzumab for HER-2/neu-positive breast cancer. Oncologist 11: 857-867, 2006.
20. Hortobagyi GN: Trastuzumab in the treatment of breast cancer. N Engl J Med 353: 1734-1736, 2005.
21. Piccart-Gebhart MJ: Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer 42: 1715-1719, 2006.
22. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R and Lupu R: Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 101: 10715-10720, 2004.
23. Menendez JA, Mehmi I, Verma VA, Teng PK and Lupu R: Pharmacological inhibition of fatty acid synthase (FAS): a novel therapeutic approach for breast cancer chemoprevention through its ability to suppress Her-2/neu (erbB-2) oncogene-induced malignant transformation. Mol Carcinog 41: 164-178, 2004.
24. Menendez JA and Lupu R: Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Arch Immunol Ther Exp 52: 414-426, 2004.
25. Menendez JA, Vellon L and Lupu R: Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp Biol Med 230: 151-154, 2005.
26. Menendez JA, Vellon L and Lupu R: Antitumoral actions of the anti-obesity drug orlistat (Xenical™) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Ann Oncol 16: 1253-1267, 2005.
27. Menendez JA, Lupu R and Colomer R: Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neuoverexpressing breast cancer. Drug News Perspect 18: 375-385, 2005.
28. Menendez JA, Vellon L and Lupu R: The antiobesity drug Orlistat induces cytotoxic effects, suppresses Her-2/neu (erbB-2) oncogene overexpression, and synergistically interacts with trastuzumab (Herceptin) in chemoresistant ovarian cancer cells. Int J Gynecol Cancer 16: 219-221, 2006.
29. Menendez JA, Vellon L and Lupu R: Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 64: 997-1001, 2005.
30. Hung MC and Wang SC: Suppressing HER2/neu-mediated cell transformation by transcriptional repressors. Breast Dis 11: 133-144, 2000.
31. Xing X, Wang SC, Xia W, Zou Y, Shao R, Kwong KY, Yu Z, Zhang S, Miller S, Huang L and Hung MC: The ets protein PEA3 suppresses HER-2/neu overexpression and inhibits tumorigenesis. Nat Med 6: 189-195, 2000.
32. Wang SC and Hung MC: Transcriptional targeting of the HER-2/neu oncogene. Drugs Today 36: 835-843, 2000.
33. Xia WY, Lien HC, Wang SC, Pan Y, Sahin A, Kuo YH, Chang KJ, Zhou X, Wang H, Yu Z, Hortobagyi G, Shi DR and Hung MC: Expression of PEA3 and lack of correlation between PEA3 and HER-2/neu expression in breast cancer. Breast Cancer Res Treat 98: 295-301, 2006. (Pubitemid 44195599)
34. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R and Polyak K: Molecular markers in ductal carcinoma in situ of the breast. Mol Cancer Res 1: 362-375, 2003.
35. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK and Koay ES: Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neupositive breast cancer. Mol Cell Proteomics 4: 1686-1696, 2005.
36. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S and Arteaga CL: Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132-4141, 2002.
37. Nahta R, Takahashi T, Ueno NT, Hung MC and Esteva FJ: P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells. Cancer Res 64: 3981-3986, 2004. (Pubitemid 38697313)
38. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yang G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC and Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 66: 1630-1639, 2006.
39. Ropero S, Menendez JA, Vazquez-Martin A, Montero S, Cortes-Funes H and Colomer R: Trastuzumab plus tamoxifen: anti-proliferative and molecular interactions in breast carcinoma. Breast Cancer Res Treat 86: 125-137, 2004.
40. Diermeier S, Horvath G, Knuechel-Clarke R, Hofstaedter F, Szollosi J and Brockhoff G: Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation. Exp Cell Res 304: 604-619, 2005.
41. Yu D, Suen TC, Yan DH, Chang LS and Hung MC: Transcriptional repression of the neu protooncogene by the adenovirus 5 E1A gene products. Proc Natl Acad Sci USA 87: 4499-4503, 1990.
42. Yu D, Matin A, Xia W, Sorgi F, Huang L and Hung MC: Liposome-mediated in vivo E1A gene transfer suppressed dissemination of ovarian cancer cells that overexpress HER-2/neu. Oncogene 11: 1383-1388, 1995.
43. Hortobagyi GN, Ueno NT, Xia W, Zhang S, Wolf JK, Putnam JB, Weiden PL, Willey JS, Carey M, Branham DL, Payne JY, Tucker SD, Bartholomeusz C, Kilbourn RG, De Jager RL, Sneige N, Katz RL, Anklesaria P, Ibrahim NK, Murray JL, Theriault RL, Valero V, Gershenson DM, Bevers MW, Huang L, Lopez-Berestein G and Hung MC: Cationic liposome-mediated E1A gene transfer to human breast and ovarian cancer cells and its biologic effects: a phase I clinical trial. J Clin Oncol 19: 3422-3433, 2001.
44. Yu Z, Xia W, Wang HY, Wang SC, Pan Y, Kwong KY, Hortobagyi GN and Hung MC: Antitumor activity of an Ets protein, PEA3, in breast cancer cell lines MDA-MB-361DYT2 and BT474M1. Mol Carcinog 45: 667-675, 2006.
45. Menendez JA and Lupu R: Oncogenic properties of the endogenous fatty acid metabolism: molecular pathology of fatty acid synthase in cancer cells. Curr Opin Clin Nutr Metab Care 9: 346-357, 2006.
46. Lupu R and Menendez JA: Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Curr Pharm Biotechnol 7: 483-493, 2006.